Ilia Belotserkovsky, Lisa M Stabryla, Monique Hunter, Jessica Allegretti, Benjamin J Callahan, Paul E Carlson, Phillip J Daschner, Maryam Goudarzi, Cyril Guyard, Scott A Jackson, Krishna Rao, Stephanie L Servetas, Harry Sokol, Jennifer A Wargo, Shawn Novick
Fecal microbiota transplantation (FMT) has been demonstrated to be efficacious in preventing recurrent Clostridioides difficile (C. difficile) infections, and is being investigated for treatment of several other diseases including inflammatory bowel disease, cancer, obesity, liver disease, and diabetes. To speed up the translation of FMT into clinical practice as a safe and standardized therapeutic intervention, additional evidence-based technical and regulatory guidance is needed. To this end in May of 2022, the International Alliance for Biological Standardization (IABS) and the BIOASTER Microbiology Technology Institute hosted a second webinar to discuss key issues still impeding the advancement and standardization of FMT...
March 21, 2024: Biologicals: Journal of the International Association of Biological Standardization